BDNF release and signaling are required for the antidepressant actions of GLYX-13

Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication

Ronald C. Kessler, Wai Tat Chiu, Olga Demler et al. · Archives of General Psychiatry · 2005 · 12.1K citations · Full text

Education, Behavioral Sciences, Psychiatry +14

Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice

Madhukar H. Trivedi, A. John Rush, Stephen R. Wisniewski et al. · American Journal of Psychiatry · 2006 · 3.9K citations

Pharmacy, Pharmacotherapy, Psychiatry +17

The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function

Michael Egan, Masami Kojima, Joseph H. Callicott et al. · Cell · 2003 · 3.9K citations · Full text

Life Sciences, Genetics, Neuroscience +8

Antidepressant effects of ketamine in depressed patients

Robert Berman, Angela Cappiello, Amit Anand et al. · Biological Psychiatry · 2000 · 3.8K citations

Medicine, Pharmacology, Psychiatry +14

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans

John H. Krystal · Archives of General Psychiatry · 1994 · 3.3K citations

Medicine, Neuroscience, Pharmacology +13